01 Automation in Specimen Handling and PreservationThe automation of specimen handling and preservation is transforming the rare biomarkers field by enhancing efficiency, minimizing human error, and ensuring sample integrity. Robotic systems are now streamlining processes such as sample collection, preparation, and storage, significantly improving workflow precision and reliability.For example, a study published in ScienceDirect in September 2023 highlighted the integration of robotic liquid handlers in bioanalytical laboratories, emphasizing their role in increasing throughput and accuracy in sample preparation. The adoption of automated systems not only ensures consistent specimen handling but also enhances reproducibility, which is crucial for the accurate analysis of rare biomarkers.As automation continues to advance, laboratories and research facilities are increasingly integrating these technologies to optimize operations and improve research outcomes.
02 Rise of Micro-Sampling TechniquesMicro-sampling techniques, such as dried blood spots (DBS) and volumetric absorptive micro-sampling (VAMS), are revolutionizing the collection of rare biomarker specimens by enabling the acquisition of small, easy-to-handle samples with minimal patient discomfort. These methods reduce the reliance on invasive procedures, making specimen collection more accessible and patient-friendly.To meet the growing demand for micro-sampling, manufacturers are actively developing innovative technologies.For instance, in November 2022, Neoteryx launched a Research Support Program that provides free Mitra micro-sampling devices to researchers, enabling them to apply remote blood collection and micro-sampling in novel studies.Such innovations are accelerating the adoption of micro-sampling techniques, further driving market expansion.
01 Advancements in Multi-Omics Research and Personalized MedicineThe integration of multi-omics technologies, including genomics, proteomics, metabolomics, and transcriptomics, is significantly driving demand for advanced specimen collection and stabilization techniques. These technologies require high-quality biomarker preservation to enable precise, multi-layered data analysis for applications in precision medicine. As a result, manufacturers are increasingly focusing on developing multimodal kits designed to enhance personalized medicine approaches.Consequently, the growing reliance on multi-omics research is reinforcing the need for reliable specimen-handling solutions, propelling market growth.
02 Rising Investments in Biobanking and Longitudinal StudiesBiobanks play a crucial role in rare biomarker research by supporting longitudinal studies that monitor disease progression over extended periods. The increasing investments in biobanking infrastructure are fueling demand for innovative stabilization technologies that ensure long-term sample viability and reliability.Such strategic investments highlight the growing importance of robust specimen collection and stabilization solutions in biomarker research.
01 Limited Standardization across LaboratoriesWhile biomarker-based diagnostics have gained prominence, rapid technological advancements have introduced complexities in protocols, procedures, and equipment, leading to inconsistencies in specimen handling. These variations impact biomarker quality and integrity, ultimately compromising the accuracy, reproducibility, and reliability of test results.Addressing these standardization challenges is essential to ensuring high-quality biomarker analysis and fostering trust in diagnostic and therapeutic applications.
01 Emergence of Digital Biomarkers in Rare Disease R&dThe emergence of digital biomarkers collected through wearable sensors, mobile applications, and AI-driven analytics is revolutionizing rare disease R&D. These biomarkers enable continuous, real-time monitoring of physiological and behavioral data, enhancing early disease detection and providing valuable insights into treatment response.By offering non-invasive, scalable, and patient-centric monitoring solutions, digital biomarkers are reshaping the landscape of rare disease diagnostics and therapeutics.The successful validation of digital biomarkers presents significant opportunities for companies to expand their portfolios into the digital rare biomarker space.
June 2026 Foresight Diagnostics and QIAGEN expanded their collaboration to advance the commercialization of a kit-based version of the CLARITY® circulating tumor DNA (ctDNA) assay, supporting standardized specimen collection, stabilization, and companion diagnostic development for hematological cancers.
May 2026 Streck launched MDx-Chex®, a new molecular quality control solution designed to preserve circulating nucleic acids and proteins across liquid biopsy workflows, strengthening quality assurance for rare biomarker specimen collection and stabilization.
April 2026 Precede Biosciences launched Precede Bio Insight™, a genome-wide liquid biopsy platform that analyzes tumor biology from a 1 mL plasma sample, expanding applications for stabilized rare biomarker specimens in precision oncology.
April 2026 Beckman Coulter Life Sciences expanded its partnership with Apostle Inc. by launching the Apostle MiniMax® High-Efficiency Isolation Kits for cell-free RNA and total cell-free nucleic acid extraction, enhancing rare biomarker preservation and downstream molecular analysis workflows.